PriceTargets.com logo

Regulus Therapeutics - RGLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 994.89%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.37 As of 03/21/2025 05:00 PM ET
▲ +0.01 (0.74%)

This chart shows the closing price for RGLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$1.37Closing price on 03/21/25:
Get New Regulus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGLS

Analyst Price Target is $15.00
▲ +994.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Regulus Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $28.00 and a low forecast of $7.00. The average price target represents a 994.89% upside from the last price of $1.37.

This chart shows the closing price for RGLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$0.68$7.51$14$21$28Closing price on 03/21/25: $1.37High$28.00Average$15.00Low$7.00




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Regulus Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/17/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/14/2024OppenheimerReiterated RatingOutperform ➝ Outperform$7.00 ➝ $7.00
8/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/2/2024OppenheimerInitiated CoverageOutperform$7.00
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/25/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$11.00 ➝ $28.00
6/25/2024HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $10.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
3/19/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$12.00 ➝ $11.00
3/18/2024Leerink PartnrsReiterated RatingOutperform
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
3/18/2024Leerink PartnersInitiated CoverageOutperform$6.00
3/13/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00
9/21/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$9.00 ➝ $12.00
9/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
6/28/2023500.comReiterated RatingReiterates
4/21/2023HC WainwrightLower TargetBuy$20.00 ➝ $9.00
11/8/2022Canaccord Genuity GroupInitiated CoverageBuy$9.00
11/7/2022Canaccord Genuity GroupInitiated CoverageBuy$9.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
1/25/2022HC WainwrightReiterated RatingBuy$20.00
9/2/2021Cantor FitzgeraldInitiated CoverageOverweight$20.00
8/11/2021HC WainwrightReiterated RatingBuy
5/14/2021HC WainwrightBoost TargetPositive ➝ Buy$15.00 ➝ $20.00
9/1/2020HC WainwrightReiterated RatingBuy
7/24/2020WedbushReiterated RatingHold$10.00
7/23/2020HC WainwrightReiterated RatingBuy
6/11/2020WedbushReiterated RatingHold$10.00
5/18/2020HC WainwrightReiterated RatingBuy$15.00
5/15/2020Needham & Company LLCInitiated CoverageHold
5/4/2020HC WainwrightReiterated RatingBuy$20.00 ➝ $15.00
(Data available from 3/21/2020 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024
  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2025
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2025
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2025

Current Sentiment

  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.37
Low: $1.35
High: $1.40

50 Day Range

MA: $1.27
Low: $0.97
High: $1.48

52 Week Range

Now: $1.37
Low: $0.83
High: $3.00

Volume

263,677 shs

Average Volume

511,870 shs

Market Capitalization

$90.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Regulus Therapeutics?

The following equities research analysts have issued reports on Regulus Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for RGLS.

What is the current price target for Regulus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Regulus Therapeutics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 994.9%. Canaccord Genuity Group Inc. has the highest price target set, predicting RGLS will reach $28.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $7.00 for Regulus Therapeutics in the next year.
View the latest price targets for RGLS.

What is the current consensus analyst rating for Regulus Therapeutics?

Regulus Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RGLS will outperform the market and that investors should add to their positions of Regulus Therapeutics.
View the latest ratings for RGLS.

What other companies compete with Regulus Therapeutics?

Other companies that are similar to Regulus Therapeutics include Verastem, Emergent BioSolutions, Vanda Pharmaceuticals, Ironwood Pharmaceuticals and XOMA. Learn More about companies similar to Regulus Therapeutics.

How do I contact Regulus Therapeutics' investor relations team?

Regulus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (858) 202-6300 and its investor relations email address is ccalsada@regulusrx.com. The official website for Regulus Therapeutics is www.regulusrx.com. Learn More about contacing Regulus Therapeutics investor relations.





Receive Regulus Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for Regulus Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.